🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital162 AstraZeneca148 Janssen Research & Development, LLC55 Hoffmann-La Roche44 Sichuan University44
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chengdu

1291 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
NCT07382375Aortic Aneurysm and Dissection
Nanjing Medical University
Not applicable
300
Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai
2027-12-31
Not yet open
Improving Quality of Informal Care for People With Schizophrenia
NCT07781748Schizophrenia
Chinese University of Hong Kong
Not applicable
228
Chengdu
2027-07-01
Not yet open
A Study of TIL in Advanced Solid Tumors (CZ)
NCT07294872Solid Tumor, Adult
Shanghai Juncell Therapeutics
Phase 1
30
Chengdu
2026-12-08
Not yet open
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861Obesity, Overweight
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
Clinical Efficacy of Modified Simiao Yongan Decoction and Endovascular Therapy for Diabetic Foot Ulcers
NCT07808502Diabetic Foot Ulcer, Damp-Heat Toxins Accumulation Syndrome
Chengdu University of Traditional Chinese Medicine
Not applicable
120
Chengdu
2026-12
Not yet open
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
NCT07258147Lung Cancer (SCLC)
Sichuan University
Phase 2
30
Chengdu
2026-10-31
Not yet open
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
NCT05048368Esophageal Cancer, Advanced Solid Tumor
Sunshine Lake Pharma Co., Ltd.
Phase 1
32
Chengdu
2026-10-30
Not yet open
The Effect of Perioperative Intravenous Lidocaine Infusion on Post-amputation Pain in Amputee Patients
NCT07783867Amputation
West China Hospital
Not applicable
200
Chengdu
2026-10-01
Not yet open
A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)
NCT07832201Influenza
Sinovac Biotech Co., Ltd
Phase 4
150
Changsha, Chengdu, Chongqing, Guangzhou, Nanjing, Wuhan
2026-10
Not yet open
Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal
NCT07800000Squamous Cell Carcinoma of the Anal Canal
Wang Xin
Phase 2
34
Chengdu
2026-09-20
Not yet open
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
NCT07649421Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
West China Hospital
Phase 2
254
Chengdu
2026-09-15
Not yet open
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
466
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou
2026-09-14
Recruiting
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
NCT07703163Solid Tumor, SGLT 2 Inhibitors
West China Hospital
Phase 1
15
Chengdu
2026-09-10
Not yet open
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC
NCT07802184Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
West China Hospital
Phase 1/2
45
Chengdu
2026-09-10
Recruiting
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
NCT07724106Ovarian Cancer, mRNA Vaccine
West China Hospital
Phase 1
9
Chengdu
2026-09-10
Recruiting
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery
NCT07676890Ovarian Cancer, mRNA Vaccine
West China Hospital
Phase 1
9
Chengdu
2026-09-10
Recruiting
Tai Chi for Cancer-Related Fatigue During Radiotherapy in Patients With Head and Neck Cancer
NCT07809776Head and Neck Neoplasms, Cancer-related Fatigue
West China Hospital
Not applicable
116
Chengdu
2026-09-10
Recruiting
Wireless Wearable Home Prehabilitation for Older Adults With NSCLC
NCT07809763Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery, Prehabilitation
West China Hospital
Not applicable
196
Chengdu
2026-09-10
Recruiting
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
NCT07807059Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
32
Chengdu
2026-09-09
Not yet open
A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
NCT07782086Breast Cancer
Shuangyue Liu
Not applicable
30
Hefei, Beijing, Nanjing, Xuzhou, Dalian, Shanghai, Xi’an, Chengdu
2026-09-07
Recruiting
The Effects of Oxytocin on Fairness Perception and Related Prosocial Behaviors
NCT07815496Healthy Adult Participants
University of Electronic Science and Technology of China
Not applicable
80
Chengdu
2026-09-05
Not yet open
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
NCT07791758Metastatic Colorectal Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
369
Guangzhou, Guilin, Nanning, Luoyang, Nanchang, Jinan, Shanghai, Chengdu
2026-09-04
Not yet open
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
NCT07751848Lupus Erythematosus, Systemic
AstraZeneca
Phase 3
417
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangdong Province, Guangzhou, Hangzhou
2026-09-04
Not yet open
Sphere-9 PAF China Study
NCT07789925Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
180
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin
2026-09-02
Not yet open
Study of SG301 for Renal AMR After Transplantation
NCT07764627Antibody Mediated Rejection
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
10
Guangzhou, Nanning, Zhengzhou, Changsha, Jinan, Chengdu, Hangzhou
2026-09-01
Not yet open
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
West China Hospital
Phase 2/3
60
Hefei, Beijing, Chengdu
2026-09-01
Not yet open
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
NCT07175389Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
West China Hospital
Phase 1/2
10
Chengdu
2026-09-01
Not yet open
Heated Humidified Oxygen in PACU Patients
NCT07778420Hypoxemia, Postoperative Complications, Anesthesia Recovery Period
Second Affiliated Hospital of Xi'an Jiaotong University
Not applicable
2,000
Luoyang, Xi'an, Xianyang, Chengdu
2026-09-01
Recruiting
A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection
NCT07051187Chronic Hepatitis B Virus (Hbv)
Jiyan Liu
Phase 1
9
Chengdu
2026-09-01
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
Takeda
Phase 2
36
Beijing, Guangdong, Nanning, Wuhan, Xi'an, Jinan, Chengdu, Hangzhou
2026-09-01
Not yet open
A Comparative Study of Delayed Endoscopic DTI and Latissimus Dorsi ±Impalnt Reconstruction Post-Mastectomy
NCT07757074Breast Cancer
Du Zhenggui
Observational
268
Chengdu
2026-09-01
Not yet open
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Eli Lilly and Company
Phase 3
2,001
Chengdu, Hefei, Jinan, Luoyang Shi, Nanjing, Ningbo, Qinhuangdao Shi, Tianjin
2026-09
Not yet open
Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events
NCT07767513Lipoprotein Disorder
Shandong Suncadia Medicine Co., Ltd.
Phase 2
60
Chengdu
2026-09
Not yet open
Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
NCT07769658Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Observational
500
Guangzhou, Zhengzhou, Shanghai, Chengdu, Tianjin, Kunming
2026-09
Not yet open
Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy
NCT07803965Acute Pancreatitis
Beijing Sungen Biomedical Technology Co., Ltd
Phase 2
129
Chengdu, Guizhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo
2026-09
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2
160
Beijing, Fuzhou, Wuhan, Nanjing, Shanghai, Chengdu, Hangzhou
2026-08-31
Not yet open
Digital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection
NCT07797075Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
West China Hospital
Not applicable
222
Chengdu
2026-08-31
Not yet open
Rehabilitation With Wearable Monitors for Post-Lung Cancer Surgery
NCT07733492Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
West China Hospital
Not applicable
126
Chengdu
2026-08-31
Recruiting
Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT07076836Lung Cancer (NSCLC), Immune Checkpoint Blockade, Electroacupuncture
West China Hospital
Not applicable
82
Chengdu
2026-08-31
Not yet open
Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer
NCT07811076Locally Advanced Rectal Cancer (LARC)
Xuelei Ma MD
Phase 1/2
140
Chengdu
2026-08-31
Not yet open
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
NCT07745257HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Recruiting
Online Sharing for Head & Neck Cancer Support
NCT07766226Head and Neck Squamous Cell Carcinoma
West China Hospital
Not applicable
120
Chengdu
2026-08-28
Recruiting
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07779252Moderate to Severe Glabellar Lines
Ipsen
Phase 3
160
Guangzhou, Changsha, Nanjing, Wuxi, Jing’an, Chengdu, Hangzhou, Beijing
2026-08-25
Recruiting
A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma
NCT07732023Asthma (Diagnosis)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
36
Chengdu
2026-08-25
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Baoding, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu, Chifeng
2026-08-24
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
500
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
2026-08-24
Recruiting
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
NCT07775404Obesity, Overweight
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Not yet open
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
1,500
Beijing, Cangzhou, Changchun, Chengdu, Danyang, Ganzhou, Guangzhou, Huizhou
2026-08-21
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Not yet open
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
NCT07775040Non-Small Cell Lung Cancer
Sichuan Cancer Hospital and Research Institute
Phase 2
43
Chengdu
2026-08-20
Not yet open
A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
NCT07572812Epilepsy
Shanghai UniXell Biotechnology Co., Ltd
Phase 1
12
Beijing, Zhengzhou, Chengdu
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
AstraZeneca
Phase 3
2,500
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang
2026-08-19
Not yet open
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
NCT07665996Chronic Spontaneous Urticaria (CSU)
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase 1/2
36
Chengdu
2026-08-15
Not yet open
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Nanjing, Taiyuan
2026-08-15
Recruiting
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667Esophageal Squamous Cell Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Changchun, Chengdu, Chongqing, Fuzhou, Ha’erbin, Jinan, Kunming, Luoyang
2026-08-13
Not yet open
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
NCT07751315Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Qilu Pharmaceutical Co., Ltd.
Phase 1
64
Chengdu
2026-08-11
Recruiting
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
NCT06593392Pruritus, Chronic Kidney Diseases
Vifor Fresenius Medical Care Renal Pharma
Phase 2
18
Chengdu, Guangzhou, Hangzhou, Shanghai, Wuhan, Xi'an
2026-08-04
Not yet open
Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis
NCT07587671Liver Cirrhosis, Portal Hypertension, Gastroesophageal Varices Bleeding, Esophageal Varices
West China Hospital
Not applicable
240
Chengdu, Chongqing, Xiamen
2026-08-01
Not yet open
Yanlishuang Buccal Dropping Pills for Acute Pharyngitis
NCT07761013Acute Pharyngitis
Beijing University of Chinese Medicine
Not applicable
400
Guangzhou, Guiyang, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Chengdu
2026-08-01
Recruiting
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
NCT07763301Liver Cancer, Pancreatic Cancer, Biliary Tract Cancer (BTC)
West China Hospital
Phase 1
9
Chengdu
2026-08-01
Not yet open
Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies
NCT07472933Cancer of Biliary Duct
West China Hospital
Phase 2
49
Chengdu
2026-08-01
Recruiting
The Effect and Mechanism of taVNS in Modulating Human Social Attention
NCT07798349Healthy Adult, Role of Vagal Stimulation in Oxytocin Release, Role of Vagal Stimulation in Social Attention
University of Electronic Science and Technology of China
Not applicable
120
Chengdu
2026-08-01
Not yet open
DEC003M in Prostate Cancer
NCT07657806Advanced Prostate Cancer
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Chengdu, Hangzhou, Chongqing
2026-08-01
Not yet open
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma
NCT07740993Sebaceous Gland Carcinoma
West China Hospital
Phase 2
25
Chengdu
2026-08-01
Not yet open
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
NCT07765524Primary Light Chain (AL) Amyloidosis
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
32
Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2026-08
Not yet open
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
Eli Lilly and Company
Phase 2
606
Baotou, Beijing, Chengdu, Guangzhou, Jiangyin, Jinan, Pingxiang, Shanghai
2026-08
Not yet open
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
NCT07715565Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
West China Hospital
Phase 2
66
Chengdu
2026-08
Not yet open
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
NCT07697443Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
306
Guangzhou, Meizhou, Wuhan, Changsha, Chengdu, Tianjin
2026-08
Not yet open
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
NCT07765537Primary Membranous Nephropathy
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
55
Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu
2026-08
Not yet open
Diagnostic Accuracy and Safety of the Attention-Deficit/Hyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12
NCT07683156Attention-Deficit, Hyperactivity Disorder
Chongqing Jinsaixing Medical Technology Co., Ltd
Observational
570
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Changchun, Shanghai, Chengdu
2026-07-31
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Not yet open
YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases
NCT07610707Colorectal Cancer With Liver Metastatic
West China Hospital
Phase 1
10
Chengdu
2026-07-30
Recruiting
Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection
NCT07689578Antibody Mediated Rejection After Kidney Transplantation
Turun Song
Phase 4
50
Chengdu
2026-07-30
Not yet open
YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
NCT07580261Hepatocellular Carcinoma
West China Hospital
Phase 1
10
Chengdu
2026-07-30
Recruiting
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
NCT07586202Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
68
Cheng Du Shi, Chengdu, Guangzhou, Jinan, Tianjin
2026-07-28
Recruiting
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
NCT07725939Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
UCB Biopharma SRL
Phase 2
402
Beijing, Chengdu, Hangzhou, Nanchang
2026-07-27
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
NCT07668154HNSCC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Chengdu, Shanghai
2026-07-27
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China
NCT07757152Healthy Participants Study
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1
108
Chengdu
2026-07-23
Recruiting
EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer
NCT07518979Penile Cancer
Jiyan Liu
Phase 2
60
Chengdu
2026-07-22
Recruiting
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
NCT07767630Neuroblastoma (NB)
Sichuan University
Phase EARLY_PHASE1
10
Chengdu
2026-07-21
Recruiting
Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection
NCT07704255Helicobacter Pylori Infection
Sichuan Provincial People's Hospital
Phase 4
10
Chengdu
2026-07-20
Recruiting
Efficacy and Safety of Superior Vena Cava Isolation and Pulmonary Vein Isolation for Treatment of Atrial Fibrillation
NCT07724899Atrial Fibrillation (AF)
Qiang Hu
Not applicable
200
Chengdu
2026-07-20
Recruiting
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT07557420NMOSD, Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.
Phase 3
19
Beijing, Chengdu, Dongguan, Jinan, Shanghai, Shijiazhuang, Taiyuan, Wenzhou
2026-07-20
Recruiting
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07381075Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 2
90
Chengdu
2026-07-20
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2026-07-16
Not yet open
Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer
NCT07704372Radiation-induced Dermatitis
West China Hospital
Phase 2
140
Chengdu
2026-07-15
Recruiting
Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors
NCT07583654mRNA Vaccine, Solid Tumor Cancer, Peptides, Cancer Metastatic
West China Hospital
Phase 1
18
Chengdu
2026-07-13
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
Harbin, Beijing, Cangzhou, Chengde, Chengdu, Dalian, Daqing, Hunan
2026-07-13
Recruiting
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
NCT07538804Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Guangzhou, Harbin, Zhengzhou, Chengdu
2026-07-10
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
Boehringer Ingelheim
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2026-07-10
Recruiting
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
NCT07600788Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 1
32
Chongqing, Zhengzhou, Shanghai, Chengdu, Hangzhou
2026-07-09
Recruiting
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD
NCT07567872COPD
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
48
Chengdu
2026-07-09
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
800
Baotou, Binzhou, Cangzhou, Changsha, Chengdu, Ganzhou, Haikou, Hangzhou
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
2,000
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
AstraZeneca
Phase 3
900
Binzhou, Changsha, Chengdu, Hangzhou, Jinan, Liaocheng, Liuzhou, Luoyang
2026-07-06
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
NCT07614152Turner Syndrome
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
84
Anyang, Beijing, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2026-07-05
Not yet open
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
NCT07655661Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Ming Liu
Phase 2
52
Chengdu
2026-07-01
Not yet open
Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients
NCT07656493Invasive Fungal Infection, Solid Organ Transplantation, Opportunistic Infections
Sichuan Provincial People's Hospital
Observational
120
Chengdu
2026-07-01
Not yet open
Abrupt Discontinuation Versus Gradual Tapering of Propranolol in Infantile Hemangioma
NCT07665177Infantile Hemangioma (IH)
West China Hospital
Phase 4
110
Chengdu
2026-07-01
Rows per page Showing 1–100 of 1291
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,291 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

732 of the 1,291 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 177 have not yet opened recruitment, 354 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chengdu), 1,291 studies
PhaseStudiesRecruitingShare
Phase 341920232.5%
Phase 221011816.3%
Not applicable19410415%
Phase 114710711.4%
Observational128779.9%
Phase 1/2110718.5%
Phase 2/334212.6%
Phase EARLY_PHASE125181.9%
Phase 424141.9%

Most active sponsors

Lead sponsors with the most studies (Chengdu)
Lead sponsorStudiesRecruiting
West China Hospital162100
AstraZeneca14878
Janssen Research & Development, LLC5520
Hoffmann-La Roche4418
Sichuan University4428
Eli Lilly and Company4327
Sanofi2715
University of Electronic Science and Technology of China2523
Boehringer Ingelheim2018
Sichuan Provincial People's Hospital1810
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.